Back to search
Chronic Kidney Disease Mineral and Bone Disorder
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Chronic Kidney Disease Mineral and Bone Disorder trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Chronic Kidney Disease Mineral and Bone Disorder trials you may qualify forThe proposed pilot feeding study aims to explore novel pathways in phosphate metabolism and identify new biomarkers, as well as to develop a compound index for…
The prevalence of chronic kidney disease (CKD) in the adult population is estimated to 10%. CKD increases risk of bone fractures, cardiovascular disease and dea…
The aim of the study is to assess the association between the calcium and phosphorus balance and the stage of kidney disease measured by creatinine clearence in…
This study aims to integrate bone measurements (including bone turnover markers (BTM), bone mineral density (BMD) measurement, vertebral fracture assessment (VF…
Hyperphosphatemia management is initially based on restricting dietary phosphorus intake. Hyperphosphatemia is almost always seen in patients on dialysis and ma…
Treatment of renal osteodystrophy is impeded by the lack of practical and accurate tools to determine underlying bone turnover. Gold standard bone biopsy is not…
Parathyroid hormone (PTH) remains the central biomarker to classify CKD-metabolic bone disease (CKD-MBD) in hemodialysis patients. While PTH-values are known to…
Persons with chronic kidney disease (CKD) have a 3-fold increased risk of bone fracture and a 10-fold increased risk of cardiovascular disease than the general…
INTRODUCTION You have been asked to participate in a research study of patients with chronic kidney disease to assess whether a probiotic supplement (a commerci…